Key Insights

Highlights

Success Rate

86% trial completion

Published Results

12 trials with published results (19%)

Research Maturity

51 completed trials (80% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

12.5%

8 terminated out of 64 trials

Success Rate

86.4%

-0.1% vs benchmark

Late-Stage Pipeline

3%

2 trials in Phase 3/4

Results Transparency

24%

12 of 51 completed with results

Key Signals

12 with results86% success

Data Visualizations

Phase Distribution

58Total
Not Applicable (4)
P 1 (18)
P 2 (34)
P 3 (2)

Trial Status

Completed51
Terminated8
Recruiting2
Withdrawn1
Not Yet Recruiting1
Active Not Recruiting1

Trial Success Rate

86.4%

Benchmark: 86.5%

Based on 51 completed trials

Clinical Trials (64)

Showing 20 of 20 trials
NCT05969821Not Yet Recruiting

Clonal Hematopoiesis of Immunological Significance

NCT00544115Phase 2Active Not Recruiting

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

NCT03434730Phase 2Completed

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

NCT02808858RecruitingPrimary

Italian Network MDS Registry

NCT02760238Recruiting

Myeloproliferative Neoplasms (MPNs) Patient Registry

NCT00611351Phase 2Completed

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

NCT00075816Phase 3Completed

Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)

NCT00003816Phase 2Completed

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

NCT00274820Phase 2Completed

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder

NCT00068523Not ApplicableCompleted

Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

NCT00054236Phase 1Completed

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

NCT00053989Phase 2Completed

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

NCT00036790Phase 1Completed

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

NCT00052832Phase 2Completed

Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

NCT00044954Phase 2Completed

Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

NCT00425477Phase 2Completed

Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT00281814Completed

Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant

NCT00530218Phase 2Completed

Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant

NCT00290628Not ApplicableTerminated

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

NCT00006239Phase 1Completed

Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer

Scroll to load more

Research Network

Activity Timeline